Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor With Fractionated Gemtuzumab Ozogamicin (CLAG-GO) for the Treatment of Patients With Persistent, Relapsed or Refractory Acute Myeloid Leukemia

NCT04050280 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT04050280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04050280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor With Fractionated Gemtuzumab Ozogamicin (CLAG-GO) for the Treatment of Patients With Persistent, Relapsed or Refractory Acute Myeloid Leukemia
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 2
Overall status
Recruiting
Start date
November 1, 2019
Completion date
February 29, 2028
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia recurrent, acute myeloid leukemia, adult, acute myeloid leukemia, relapsed, adult